Plaque Rupture and Thrombosis
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared on X:
“Plaque rupture with thrombosis drives ACS, and thin-cap fibroatheroma is the archetypal high-risk plaque. There are consistent features of vulnerability across imaging modalities (large plaque burden, small MLA, TCFA, high LCBI, positive remodelling, etc.), with risk increasing when multiple features coexist. Yet absolute event rates remain low, consistent with pathology data showing most plaque ruptures are clinically silent.
So should we prophylactically stent high-risk plaques? According to this Viewpoint, completed trials (PROSPECT ABSORB, PREVENT) suggest no durable reduction in death or MI versus optimal medical therapy—benefits are limited to fewer revascularisations, at the cost of many unnecessary PCIs. With modern medical therapy, a wait-and-see strategy appears safe, avoiding most interventions without adverse consequences. For now, data favor surveillance and aggressive medical therapy over preventive PCI.
READ THE VIEWPOINT HERE.
Stay updated with Hemostasis Today.
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor
-
Jan 16, 2026, 04:51Higher-Dose Clotting Factor Prophylaxis Does Not Reduce Postpartum Hemorrhage in Women with von Willebrand Disease
-
Jan 16, 2026, 04:48Reza Shojaei on Plasma Donation as Life-Changing Medicine in Motion
-
Jan 16, 2026, 04:11Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
-
Jan 16, 2026, 04:11Why is DVT More Common In the Left Leg? Dr Raheel Moazzam’s New Study Gives Answers!
-
Jan 15, 2026, 22:00Maira Dastgir N on Microvascular Dysfunction in Geriatrics